ERBB2, erb-b2 receptor tyrosine kinase 2, 2064

N. diseases: 995; N. variants: 85
Disease: Locally advanced breast cancer ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 AlteredExpression disease BEFREE Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. 11289122 2001
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 AlteredExpression disease BEFREE Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. 11872285 2002
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Coamplification of erbB-2 and topoisomerase IIalpha is significantly associated with favorable local response to anthracycline-based therapy in LABC. 11948114 2002
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE HER2 and topoII amplification status and the response to preoperative doxorubicin chemotherapy were analysed in 67 locally advanced breast cancer patients. 12628842 2003
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Treatment-naive women with HER2-overexpressing locally advanced breast cancer, with or without metastatic disease, were included. 14715110 2003
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Our study attempts to evaluate the effects of neoadjuvant chemotherapy on HER-2/neu status in locally advanced breast cancer. 16286910 2005
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. 17324279 2007
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 AlteredExpression disease BEFREE HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies. 17986623 2008
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. 18940745 2008
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. 20113825 2010
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. 20973534 2010
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer. 22561335 2012
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 GeneticVariation disease BEFREE Trastuzumab and chemotherapy is the current standard of care in HER2+ early or locally advanced breast cancer, but there are scanty literature data of its real world effectiveness. 23604446 2013
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE This multicenter single-arm phase II study evaluated the addition of pazopanib to concurrent weekly paclitaxel following doxorubicin and cyclophosphamide as neoadjuvant therapy in human epidermal growth factor receptor (HER2)-negative locally advanced breast cancer (LABC). 25542269 2015
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Eligible women with HER2-negative locally advanced breast cancer received ixabepilone 40 mg/m(2) plus cyclophosphamide 600 mg/m(2) on day 1 of each 21-day cycle. 26507191 2015
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE A high HER2 FISH ratio is a predictor of pCR in patients with HER2+ LABC who receive NST-T. 26659222 2016
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. 26927446 2016
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Neoadjuvant treatment based on the combination of trastuzumab plus chemotherapy is the standard of care in patients with HER2-positive early or locally advanced breast cancer. 26951122 2016
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and T-DM1 + docetaxel ± pertuzumab in patients with HER2-positive locally advanced breast cancer (LABC). 27052654 2016
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. 27693116 2017
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE The standard treatment for LABC is neoadjuvant chemotherapy, with or without anti-Her2 therapy, followed by surgery, radiotherapy, and adjuvant systemic treatment if appropriate. 27889595 2017
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Baseline PET parameters measured before neoadjuvant treatment have prognostic values in ER+/HER2- locally advanced breast cancer patients. 28057031 2017
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE Changes in hormone receptor status, HER2 status and Ki-67 occurred after NAC in patients with LABC. 28730768 2019
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients. 28816986 2017
CUI: C3495949
Disease: Locally advanced breast cancer
Locally advanced breast cancer 		0.100 Biomarker disease BEFREE The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis. 29057208 2017